Journal
BRITISH JOURNAL OF CANCER
Volume 128, Issue 7, Pages 1320-1332Publisher
SPRINGERNATURE
DOI: 10.1038/s41416-023-02147-8
Keywords
-
Categories
Ask authors/readers for more resources
This study developed a plasma extracellular circRNA-based signature that can predict overall survival in mCRPC patients undergoing abiraterone therapy.
BackgroundWe aimed to develop and validate a plasma extracellular vesicle circular RNA (circRNA)-based signature that can predict overall survival (OS) in first-line abiraterone therapy for metastatic castration-resistant prostate cancer (mCRPC) patients.MethodsIn total, 582 mCRPC patients undergoing first-line abiraterone therapy from four institutions were sorted by three phases. In the discovery phase, 30 plasma samples from 30 case-matched patients with or without early progression were obtained to generate circRNA expression profiles using RNA sequencing. In the training phase, differentially expressed circRNAs were examined using digital droplet PCR in a training cohort (n = 203). The circRNA signature was constructed using a least absolute shrinkage and selection operator Cox regression to predict OS. In the validation phase, the prognostic ability of this signature was prospectively validated in two external cohorts (Cohort I, n = 183; Cohort II, n = 166).ResultsWe developed a five-circRNA signature, based on circCEP112, circFAM13A, circBRWD1, circVPS13C and circMACROD2, which successfully stratified patients into high-risk and low-risk groups. The prognostic ability of this signature was prospectively validated in two external cohorts (P < 0.0001, P < 0.0001). Patients with high-risk scores had shorter OS than patients with low-risk scores.ConclusionThis five-circRNA signature is a reliable predictor of OS for mCRPC patients undergoing abiraterone.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available